Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials...

39
Outline Introduction Results Improvement Future plans Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas [email protected] 7/20/2013 Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Transcript of Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials...

Page 1: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Multiple Testing in Group Sequential Clinical Trials

Tian Zhao

Supervisor: Michael Baron

Department of Mathematical SciencesUniversity of Texas at Dallas

[email protected]

7/20/2013

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 2: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

1 IntroductionSequential statisticsProblem

2 ResultsBonferroni approach

3 ImprovementHolm-type stepwise methods

Truncated Sequential Probability Ratio Test

Fallback approach

4 Future plans

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 3: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Sequential statistics

Multiple testing in clinical trials

Multiple endpoints ( efficacy and safety )Multiple treatment arms or doses of a drugOverall, get an answer to several questions

Sequential / group sequential clinical trials

Interim analysis (Flector trial: stop for futility)Sequential clinical trials always have a restriction on themaximum number of sampled groups (K)

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 4: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Sequential statistics

Multiple testing in clinical trials

Multiple endpoints ( efficacy and safety )Multiple treatment arms or doses of a drugOverall, get an answer to several questions

Sequential / group sequential clinical trials

Interim analysis (Flector trial: stop for futility)Sequential clinical trials always have a restriction on themaximum number of sampled groups (K)

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 5: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Our problem

Test multiple hypotheses based on sequentially observed data,achieving a decision on each individual test

Group sequential sampling

Formulation

Goal

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 6: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Our problem

Test multiple hypotheses based on sequentially observed data,achieving a decision on each individual test

Group sequential sampling

Formulation

Goal

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 7: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Our problem

Test multiple hypotheses based on sequentially observed data,achieving a decision on each individual test

Group sequential sampling

Formulation

Goal

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 8: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Group sequential methods

Group sequential sampling

A number of group sequential procedures have been proposedfor testing ONE hypothesis.

Pocock (1977) applies repeated significance tests to groupsequential trials with equal-size groups and derives a constantcritical value on the standardized normal Z scale across allstages that control Type I error. O’Brien and Fleming (1979)propose a sequential procedure that has boundary valuesdecrease over the stages on the standardized normal Z scale

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 9: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Formulation

Observe a sequence of iid random vectors Xn, n = 1, 2, ...

Xn = (X(1)1 , ...X

(d)n ) ∈ Rd is a set of measurements on unit n.

X(j)i ∼ fj(x |θ(j))

Multiple hypotheses

Test d hypotheses:

H(j)0 : θ(j) = θ

(j)0 vs H

(j)A : θ(j) = θ

(j)1 , for j = 1, 2, ..., d

Let m = constant be the group size and T be a stopping time

Tests are based on a group sequential experiment. Data arecollected in groups of m patients.

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 10: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Sequential statisticsProblem

Goal

ControlFamilywise Type I error rate = FWER-I = P( At least oneType I error ) ≤ αFamilywise Type II error rate = FWER-II = P( At least oneType II error) ≤ βP(T ≤ K ) = 1 , T is stopping time, K = given integer =max allowed number of groups

Do it at low expected cost

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 11: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Bonferroni approach

Bonferroni approach

Bonferroni approach : control of both error rates.Choose

αj ∈ (0, 1),∑

αj = α; βj ∈ (0, 1),∑

βj = β

Test H(j)0 at level αj and power (1− βj) by any known sequential

procedure

P

d⋃j=1

Type I error on H(j)0

≤∑P(Type I error on H

(j)0

)=∑

αj = α

P

d⋃j=1

Type II error on H(j)A

≤∑P(Type II error on H

(j)A

)=∑

βj = β

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 12: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Improvement of Bonferroni Methods

Bonferroni inequality is very crude for moderate to large d, extendto Holm’s stepwise approach.

Order the log-likelihood ratio (LLR) statistics in decreasing(step-down)/increasing (step-up)

Choose stopping boundaries for the ordered LLR

Define the stopping rule and decision rules

This requires analysis of the group sequential test

Boundaries of Pocock, O’Brien-Fleming, Wang-Tsiatis testsare computed numerically, not tractable to analyze

Derive equations for Whitehead triangular test and TruncatedSPRT

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 13: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Group sequential tests

-

-

-

-

6

6

6

6

k

k

k

k

Pocock testZk O’Brien-Fleming testZk

Whitehead testZk

������

��

��������

Truncated SPRTΛk

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 14: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Derive Truncated SPRT

SPRT

Choose stopping boundaries a, b to control α and βwhere,

a =1− βα

b =β

1− αSPRT control both α, β among all sequential tests that have

P(Type I error) ≤ αP(Type II error) ≤ β

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 15: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Wald’s SPRT

6

-

@@@@@@@@@@@@@@@@@@@@@@@@@@@

���������������������������

0

b

a

Λk

k

R e j e c t H0

A c c e p t H0

t���tXXXt���t���t���t

HHHt���t���t���u

T

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 16: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT

Stopping time and Decision rule

Following SPRT approach for single hypothesis testing, truncatedSPRT is based on log-likelihood rations

Λn = lnf (x |θ1)

f (x |θ0)

Stopping time

T = min(K ,min {n : Λn /∈ (b, a)}) ≤ K

Decision rule,

δ =

{reject H0 if ΛT ≥ a or ΛT ≥ c ∩ T = Kaccept H0 if ΛT ≤ b or ΛT < c ∩ T = K

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 17: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT (cont’d)

6

-

@@@@@@@@@@@@@@@@@@@

�������������������

@@@@@@@@@

�����

0

b

a

Λk

k

c

R e j e c t H0

A c c e p t H0

K

Accept

H0

RejectH0

t���tXXXt���t���t���t

HHHt���u

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 18: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT (cont’d)

Plan

Evaluate performance of TSPRT, probabilities of Type I andType II errors.

Find equations of the stopping boundaries and the requiredgroup size to control P{Type I error} and P{Type II error}.Then develop Holm-type stepwise sequential procedures totest d hypotheses controlling familywise error rates I and II.

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 19: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT. Performance evaluation.

Evaluate probabilities of Type I and Type II errors by comparisonbetween TSPRT and SPPRT.

6

-

@@@@@@@@@@@@@@@@@@@@@@@@@@@

���������������������������

0

b

a

Λk

k

c

R e j e c t H0

A c c e p t H0

Kt���tXXXt���

t���t���tHHHt������t���

uu

Both tests reject H0

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 20: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT. Performance evaluation.

6

-

@@@@@@@@@@@@@@@@@@@@@@@@@@@

���������������������������

0

b

a

Λk

k

c

R e j e c t H0

A c c e p t H0

Kt���tXXXt���

t���t���tHHHt���@

@@tAAAAAAu

uTSPRT rejects H0

but SPRT accepts it

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 21: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT. Performance evaluation.

6

-

@@@@@@@@@@@@@@@@@@@@@@@@@@@

���������������������������

0

b

a

Λk

k

c

R e j e c t H0

A c c e p t H0

Kt���tXXXt���

t���tHHHt tXXX@@@@@@

tu

u

Both tests accept H0

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 22: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT. Performance evaluation.

6

-

@@@@@@@@@@@@@@@@@@@@@@@@@@@

���������������������������

0

b

a

Λk

k

c

R e j e c t H0

A c c e p t H0

Kt���tXXXt���

t���tHHHt tXXX������tu

u

TSPRT accepts H0

but SPRT rejects it

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 23: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Probability of Type I Error

Choose c to attain P(Type I error |TSPRT ) ≤ α.

Let ΛK =∑Km

j=1 lnf (xj |θ1)f (xj |θ0) . For a given α1=level for SPRT,

P(Type I error |TSPRT )

= PH0(Type I error |SPRT )

+PH0({Λ1, ...ΛK−1 ∈(b, a)} ∩ {ΛK ∈ [c , a)} ∩ {Λn ≤ b before Λn ≥ a})−PH0({Λ1, ...ΛK−1 ∈(b, a)} ∩ {ΛK ∈(b, c)} ∩ {Λn ≥ a before Λn ≤ b})≤ α1 + P(A)− P(B)

We need to make P(A) ≤ α− α1

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 24: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Type I error

P(A) ≤ PH0(ΛK ∈ [c, a))PH0(Λn ≤ b before Λn ≥ a|ΛK ≥ c)

≤ PH0(ΛK ≥ c)PH0(Λn ≤ b before Λn ≥ a|ΛK ≥ c)

≤ PH0(ΛK ≥ c)PH0(Λn ≤ b before Λn ≥ a|ΛK = c)

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 25: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT (cont’d)

Derivations

Assumption: ( General ) Exponential familyTest

H0 : θ = θ0 vs HA : θ = θ1.

Exponential family is written in the canonical form withη = canonical parameter as follows,

f (x |η) = f (x |0)eηx−ψ(η)

where, ψ(0) = 0 and µ(η) = EX = ψ′(η), VarX = ψ”(η)

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 26: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT (cont’d)

Chernoff Inequality

In general case, we have

P(n∑

i=1

Zj ≥ ny) ≤ e−n supt≥0{ty−ψz (t)}

here,

Z = lnf (x |θ1)

f (x |θ0), c = ny

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 27: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT (cont’d)

Normal as example

Observe X1,X2, ...,Xn ∼ N(θ, σ2), we can write it as

f (x |θ, σ2) =1√2πσ

e−x2

2σ2 eθxσ2−

θ2

2σ2

here,

η =θ

σ2, f (x |0) =

1√2πσ

e−x2

2σ2 , ψx(η) =σ2η2

2

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 28: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Truncated SPRT (cont’d)

Normal as example

By Chernoff Inequality,

supt≥0{ty − ψz(t)} attained at t̂ = [ψ′z ]−1(y)

Therefore,

P(n∑

i=1

Zj ≥ ny) ≤ e−n{ σ2y2

2(θ1−θ0)2+

12y+

(θ1−θ0)2

8σ2 }

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 29: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Type I error

P(A) ≤ PH0(ΛK ∈ [c, a))PH0(Λn ≤ b before Λn ≥ a|ΛK ≥ c)

≤ PH0(ΛK ≥ c)PH0(Λn ≤ b before Λn ≥ a|ΛK ≥ c)

≤ PH0(ΛK ≥ c)PH0(Λn ≤ b before Λn ≥ a|ΛK = c)

Hence, we have

P(A) ≤ 1− α1ec

1− α1βe−n{ σ2c2

2n2(θ1−θ0)2+

c2n+

(θ1−θ0)2

8σ2 } ≤ α− α1

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 30: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Type II error

For α1=level for SPRT ∈ (0, α) , β1= power for SPRT ∈ (0, β)Let a = − lnα1, and b = − lnβ1

Choose c1 to control Type I error:

1− α1ec1

1− α1β1e−n{ σ2c21

2n2(θ1−θ0)2+

c12n+

(θ1−θ0)2

8σ2 } ≤ α− α1

Choose c2 to control Type II error:

1− β1ec21− α1β1

e−n{ σ2c22

2n2(θ1−θ0)2−

c22n+

(θ1−θ0)2

8σ2 } ≤ β − β1

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 31: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Type II error

Therefore, if θ1−θ0σ > 0, we have,

c1 ≥

(√−2

nln (α− α1)(1− α1β1)− (θ1 − θ0)

)n(θ1 − θ0)

σ

c2 ≤

(−√−2

nln (β − β1)(1− α1β1) +

(θ1 − θ0)

)n(θ1 − θ0)

σ

Minimize n to control both Type I error and Type II error

n∗ =2σ2

(√− ln (α− α1)(1− α1β1) +

√− ln (β − β1)(1− α1β1)

)2(θ1 − θ0)2

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 32: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Stepwise method for Truncated SPRT

Test d hypotheses:

H(j)0 : θ(j) = θ

(j)0 vs H

(j)A : θ(j) = θ

(j)1 j = 1, 2, ..., d

Test statistics Λ(j)k =

∑ln

fj (X(j)i |θ

(j)1 )

fj (X(j)i |θ

(j)0 )

Order test statistics Λ[1]k ≥ ... ≥ Λ

[d ]k , let H

(j)0 be the

corresponding tested null hypotheses arranged in the sameorder.

aj = − ln α−α1d−j+1 , bj = ln β−β1

j

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 33: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Stepwise method for Truncated SPRT(cont’d)

Decision rule (reject one by one, accept all)

If Λ[1]k ≤ b1 ⇒ stop, accept H

[1]0 , ...,H

[d ]0

If Λ[1]k ≥ a1 ⇒ reject H

[1]0 , go to H

[2]0

If Λ[1]k ∈ (b1, a1), ⇒ continue sampling

......

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 34: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Stepwise method for Truncated SPRT(cont’d)

At k = K ,

If Λ[j]K /∈ (bj , aj), ⇒ stop

If Λ[j]K ∈ (bj , aj),

Λ[j]K > cj ⇒ stop, reject

Λ[j]K < cj ⇒ stop, accept

This stepwise method can control FWER-I and FWER-II

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 35: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Holm-type stepwise methodsFallback approach

Fallback approach

Pocock Test

Pocock derives the constant boundary [−Cp,Cp] on thestandardized Z scale, if Z /∈ [−Cp,Cp], stop and reject H0,otherwise, keep sampling, after K groups, if Z /∈ [−Cp,Cp], stopand reject H0, otherwise, stop and accept H0

Fallback method for Pocock: recycle βj on all H(j)0 that were

rejected, then at k = K , test remaining H(j)0 at higher βj

βj(K ) =βj(1)

1−∑

i :H(i)0 was rejected

βi

Testing with higher β means that we can accept more often,expand the acceptance region. P(reject|H0) reduces, we canshrink boundary [−Cp,Cp] to meet the α level, and then reduce m.

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 36: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Future plans

Use stepwise approach to multiple hypotheses starting fromvarious standard group sequential methods

Evaluate performance of fallback procedures, compare fallbackand stepwise testing approaches

Composite hypotheses and nuisance parameters. Sequentialt-test.

Examples of clinical data

Thank you!

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 37: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Future plans

Use stepwise approach to multiple hypotheses starting fromvarious standard group sequential methods

Evaluate performance of fallback procedures, compare fallbackand stepwise testing approaches

Composite hypotheses and nuisance parameters. Sequentialt-test.

Examples of clinical data

Thank you!

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 38: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Future plans

Use stepwise approach to multiple hypotheses starting fromvarious standard group sequential methods

Evaluate performance of fallback procedures, compare fallbackand stepwise testing approaches

Composite hypotheses and nuisance parameters. Sequentialt-test.

Examples of clinical data

Thank you!

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials

Page 39: Multiple Testing in Group Sequential Clinical Trials · Multiple testing in clinical trials Multiple endpoints ( e cacy and safety ) Multiple treatment arms or doses of a drug Overall,

OutlineIntroduction

ResultsImprovementFuture plans

Future plans

Use stepwise approach to multiple hypotheses starting fromvarious standard group sequential methods

Evaluate performance of fallback procedures, compare fallbackand stepwise testing approaches

Composite hypotheses and nuisance parameters. Sequentialt-test.

Examples of clinical data

Thank you!

Tian Zhao Supervisor: Michael Baron Multiple Testing in Group Sequential Clinical Trials